Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 3, 2009, Pages 281-284

  Yoo, H D ^a   Park, S A ^a   Cho, H Y ^b   Lee, Y B ^a  

^a Chonnam National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; GENE FREQUENCY; GENOTYPE; HALF-LIFE; HUMANS; KOREA; MALE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TETRAZOLES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 69449091820     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.90     Document Type: Article

References (30)

1. Kimura, Y., Tani, T., Kanbe, T. & Watanabe, K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35, 1144-1149 (1985). (Pubitemid 15030828)
2. Uchikawa, T., Murakami, T. & Furukawa, H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 42, 322-324 (1992).
3. Dawson, D.L., Cutler, B.S., Meissner, M.H. & Strandness, D.E. Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98, 678-686 (1998).
4. Bramer, S.L., Forbes, W.P. & Mallikaarjun, S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin. Pharmacokinet. 37 (suppl. 2), 1-11 (1999). (Pubitemid 30171182)
5. Suri, A., Forbes, W.P. & Bramer, S.L. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women. J. Clin. Pharmacol. 38, 144-150 (1998). (Pubitemid 28117370)
6. Akiyama, H., Kudo, S. & Shimizu, T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 35, 1133-1140 (1985). (Pubitemid 15030826)
7. Abbas, R. et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum. Exp. Toxicol. 19, 178-184 (2000). (Pubitemid 30411779)
8. Hiratsuka, M. et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab. Dispos. 35, 1730-1732 (2007). (Pubitemid 47481597)
9. Wandel, C., Witte, J.S., Hall, J.M., Stein, C.M., Wood, A.J. & Wilkinson, G.R. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′- promoter region polymorphism. Clin. Pharmacol. Ther. 68, 82-91 (2000). (Pubitemid 30609830)
10. Min, D.I. & Ellingrod, V.L. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 25, 305-309 (2003).
11. Hesselink, D.A. et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76, 545-556 (2004).
12. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
13. Frohlich, M., Hoffmann, M.M., Burhenne, J., Mikus, G., Weiss, J. & Haefeli, W.E. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br. J. Clin. Pharmacol. 58, 443-444 (2004). (Pubitemid 39312470)
14. Kivisto, K.T. et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525 (2004).
15. Macphee, I.A. et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79, 499-502 (2005).
16. Mouly, S.J. et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. 78, 605-618 (2005).
17. Adedoyin, A., Prakash, C., O'Shea, D., Blair, I.A. & Wilkinson, G.R. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4, 27-38 (1994). (Pubitemid 24106121)
18. Ward, S.A., Helsby, N.A., Skjelbo, E., Brosen, K., Gram, L.F. & Breckenridge, A.M. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br. J. Clin. Pharmacol. 31, 689-692 (1991).
19. Klotz, U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 44, 297-302 (2006). (Pubitemid 44043771)
20. Kim, K.A., Park, P.W., Hong, S.J. & Park, J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236-242 (2008).
21. Weiss, J. et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49, 196-204 (2009).
22. de Morais, S.M., Wilkinson, G.R., Blaisdell, J., Nakamura, K., Meyer, U.A. & Goldstein, J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422 (1994). (Pubitemid 24982362)
23. De Morais, S.M., Wilkinson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K. & Goldstein, J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598 (1994). (Pubitemid 24334747)
24. Goldstein, J.A. et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64 (1997).
25. Chowbay, B., Cumaraswamy, S., Cheung, Y.B., Zhou, Q. & Lee, E.J.D. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 89-96 (2003). (Pubitemid 36259588)
26. Xie, H.G., Kim, R.B., Wood, A.J. & Stein, C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
27. Yamada, S. et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 36, 669-672 (2001). (Pubitemid 33040939)
28. Suri, A., Forbes, W.P. & Bramer, S.L. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin. Pharmacokinet. 37 (suppl. 2),61-68 (1999). (Pubitemid 30171188)
29. van Schaik, R.H.N., van der Heiden, I.P., van den Anker, J.N. & Lindemans, J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48, 1668-1671 (2002).
30. Fiegenbaum, M. et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78, 551-558 (2005). (Pubitemid 41698910)